AF
HRMY icon

Avanza Fonder’s Harmony Biosciences HRMY Stock Holding History

Avanza Fonder’s Portfolio HRMY Stock Details HRMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-2,924
Closed -$80.6K – 512
2025
Q3 		$80.6K Hold
2,924
– – ﹤0.01% 418
2025
Q2 		$92.4K Hold
2,924
– – ﹤0.01% 415
2025
Q1 		$95.1K Sell
2,924
-1,276
-30% -$45.7K ﹤0.01% 440
2024
Q4 		$145K Buy
+4,200
New +$144K ﹤0.01% 411

Other funds holding HRMY

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Avanza Fonder's HRMY Position: Q4 2025 in Review

Avanza Fonder sold out of Harmony Biosciences (HRMY) in Q4 2025, closing a stake of 2,924 shares — an estimated $80.6K sold.

Avanza Fonder first reported a position in HRMY in Q4 2024 and held it in 4 quarters. The position peaked at $145K in Q4 2024. 323 funds tracked by Wall St. Rank hold HRMY as of Q4 2025.

  • Avanza Fonder reported no remaining Harmony Biosciences position as of Q4 2025 after selling out during the quarter.
  • Avanza Fonder sold 2,924 Harmony Biosciences shares in Q4 2025, an estimated $80.6K.
  • Avanza Fonder first reported a position in Harmony Biosciences in Q4 2024 and held it in 4 quarters.
  • Avanza Fonder's Harmony Biosciences position peaked at $145K in Q4 2024.
  • 323 funds tracked by Wall St. Rank held Harmony Biosciences as of Q4 2025.

Based on Avanza Fonder's 13F filing for Q4 2025, filed 12 Jan 2026.